Thursday, January 3, 2008

Sciele Pharma Announces FDA Approval of New Sular Formulation

ATLANTA--(BUSINESS WIRE)--Jan 2, 2008 - Sciele Pharma, Inc. (NASDAQ: SCRX) today announced that the U.S. Food & Drug Administration (FDA) has approved all four dosage strengths of the new Sular(R) formulation. The new Sular formulation, which utilizes SkyePharma's (LSE:SKP) patented GEOMATRIX(TM) technology, provides a lower dose of Sular for each of its current doses. The Company expects to launch the new Sular formulation during the first quarter of 2008.

Patrick Fourteau, Chief Executive Officer of Sciele Pharma, said, "We are excited about this approval by the FDA for the new Sular formulation. This validates our product development and regulatory capabilities, as we have become a fully integrated pharmaceutical company."

No comments: